PijlsPA, GilissenLP. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti–TNF-alpha therapy–induced dermatological side effects. Dig Liver Dis, 2016; 48(11):–.
2.
FleisherM, MarsalJ, LeeSD, et al.Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci, 2018; 63(4):825–833.
3.
SmithMK, NicholsonC, Parks-MillerA, et al.Hidradenitis suppurativa: an update on connecting the tracts. F1000Res, 2017; 6:1272.
4.
PouldarD, ElsensohnA, OrtenzioF, et al.Nodular vasculitis in a patient with Crohn's disease on vedolizumab. Am J Dermatopathol, 2018; 40(3):e36–e37.
5.
KocharB, JiangY, WinnA, et al.The early experience with vedolizumab in the United States. Crohns Colitis 360, 2019; 1(3):otz027.
6.
SchechnerJS, EdelsonRL, McNiffJM, et al.Integrins alpha4beta7 and alphaEbeta7 are expressed on epidermotropic T cells in cutaneous T cell lymphoma and spongiotic dermatitis. Lab Invest, 1999; 79(5):601–607.
